Team

Dan is a Managing Director with OMX Ventures. Dan brings over 16 years of experience in venture capital investing, life science strategy consulting, and biomedical research to the OMX team. Prior to OMX, Dan was a Principal with Mérieux Equity Partners where he led over $30M in direct investments into therapeutics and life science tools companies. Dan has also spent 5 years with L.E.K. Consulting conducting life science corporate strategy and M&A advisory work, and 3 years as a professional political operative on various Congressional campaigns around the U.S.

Education: PhD in Biomedical Sciences from the University of California, San Diego, and a BA in Biology from Rhode Island College

Linkedin ↗

Craig is a Managing Director with OMX Ventures. Prior to OMX, Craig managed a multi-family office where he led investments in 20+ early-stage startups in bio-tools, biotech, cyber security and specialty technology. Four of those investments are now valued at over $1B. Craig has served as a Director or Board Observer for many transformational companies, including Twist Bioscience (NASDAQ: TWST) and QuantaLife (NASDAQ: BIO).  In a past life, Craig was a software product manager at 3 exited startups.

Education: AB from Stanford University with distinction and Phi Beta Kappa; MBA from Northwestern University Kellogg; MS in industrial engineering from Northwestern University. Pursuing MS in biotechnology degree at Johns Hopkins University

Linkedin ↗

Jamie is a Vice President with OMX Ventures. Prior to OMX Jamie developed deep experience in early-stage Biotech investing and company creation while working on the investment team at RA Capital.  In that role he served on the board of Enara Bio, Avilar Therapeutics, and Endor Therapeutics. Before joining RA, he was a Director at Boehringer Ingelheim Venture Fund and served as a Board Director of both Tilos Therapeutics (acquired by Merck & Co.) and Rewind Therapeutics.

Education: PhD in Molecular and Cellular Biology from the University of Notre Dame and a BS in Biology with a minor in Chemistry from Hillsdale College

Linkedin ↗

Fred is a Venture Partner with OMX Ventures. He has extensive experience in the healthcare industry with senior leadership roles leading strategy and corporate development in both small and large organizations. Prior to OMX, Fred was Chief Business Officer of MeMed Diagnostics Ltd, an Israel/Boston-based disruptive commercial stage technology company and had responsibility for Corporate Strategy and Corporate Development. During his tenure, the company executed several high value partnerships, and raised an additional $90M of equity financing. Prior to joining MeMed, Fred held leadership positions at Versant Ventures, Northern Biologics, bioMérieux and T2 Biosystems. He also currently serves as an Independent Director on the Board of QVella Corporation and CTRL Therapeutics and holds an Adjunct Professor position at the University of Toronto, faculty of Medicine, where he teaches a graduate level course on entrepreneurship in life sciences.

Education: PhD in Molecular and Medical Genetics from the University of Toronto and Bachelors of Science from McGill University

Linkedin ↗